Latest Breaking News On - Imunon inc - Page 6 : comparemela.com
Imunon (IMNN) Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Imunon Inc (NASDAQ: IMNN) announces interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001 in its Phase 1/2 OVATION 2 Study of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) for newly diagnosed with advanced epithelial ovarian, fallopian tube
Imunon Inc IMNN announces interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001 in its Phase 1/2 OVATION 2 Study of…
Imunon (NASDAQ:IMNN – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $12.00 price objective on the stock. Imunon Stock Performance Shares of NASDAQ IMNN traded down $0.02 during midday trading on Friday, reaching $1.13. […]
vimarsana © 2020. All Rights Reserved.